AzTrials
AzTrials

Microbiome AnalysisNCT07456579

Alcohol and Cannabis Use Among Pregnant Slovenian Women

An observational study of Microbiome Analysis and Drug Abuse in Pregnancy, run by University Medical Centre Ljubljana at 1 site in Slovenia.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of the study is to determine the prevalence of alcohol and drug use among Slovenian pregnant women. Alcohol and drug use during pregnancy has significant effects on the foetus and has short- and long-term health consequences. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
How many people
600 participants
Where
1 siteSlovenia
Study dates
5 May 2024to Sep 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: * Random and anonymous meconium samples collected across Slovenian maternity hospitals during the defined study period. Meconium samples will be randomly selected from routine clinical waste (medical waste) generated in maternity hospital, in accordance with the approval of the national ethics committee. * Postpartum women who voluntarily participated by completing the structured questionnaire.

Who may be able to join

  • Randomly selected meconium samples collected from newborns delivered at the participating maternity hospital during the study period.

Who cannot join

  • Meconium samples of insufficient quantity or quality for biomarker or microbiome analyses.
  • Meconium passed in utero (meconium stained amniotic fluid)
  • Probability sampling will be applied to the selection of meconium samples, which will be collected randomly. In contrast, postpartum women will be recruited upon invitation, representing a non-probability (convenience) sample.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Slovenia1 site
  • University medical centre Ljubljana

    Ljubljana, 1000

Other trials in Slovenia

About this study

Official title: Assessment of Alcohol and Cannabis Use Among Pregnant Women in Slovenia and Meconium Microbiome Analysis of Positive Samples

The aim of the study is to determine the prevalence of alcohol and drug use among Slovenian pregnant women. Alcohol and drug use during pregnancy has significant effects on the foetus and has short- and long-term health consequences. One of the most serious consequences is foetal alcohol syndrome, which is characterised by congenital anomalies, cognitive impairment and growth deficits. The prevalence of alcohol and drug use during pregnancy will be investigated in collaboration with the National Institute of Public Health, the Institute of Forensic Medicine of the Faculty of Medicine, University of Ljubljana, Institute Jozef Stefan and the Clinical Department of Neonatology of the Paediatric Clinic, University Clinical Centre Ljubljana, using two different methods. A cross-sectional study will be conducted on a nationally representative sample of meconium samples. Meconium samples will be collected from maternity hospitals in Slovenia. Biomarkers for alcohol and illicit drugs will be determined in the meconium samples. Meconium samples will be collected anonymously. National survey on the lifestyle will be conducted in Slovenian maternity hospitals, including questions on alcohol and drug use during pregnancy. The survey will be anonymous and not related to meconium sampling; participation in the survey will be voluntary. Data linkage between questionnaire responses and meconium analysis will be performed only within the additional subgroup of participants who provided informed consent. Meconium samples that will test positive for either alcohol of cannabis will be analysed for microbiome. For every positive meconium sample, two negative samples will be analysed.

Read the detailed description

The aim of the study is to determine the prevalence of alcohol and cannabis use among Slovenian pregnant women. Alcohol and drug use during pregnancy has significant effects on the foetus and has short- and long-term health consequences. One of the most serious consequences is foetal alcohol syndrome (FAS), which is characterised by congenital anomalies, cognitive impairment and growth deficits. Another health effect of prenatal alcohol exposure is foetal alcohol spectrum disorder (FASD), which is characterised by impairment of the central nervous system and leads to behavioural and cognitive problems, attention deficit disorder, executive dysfunction and memory problems. Consequently, children affected by maternal alcohol abuse have poorer school performance, lower education, psychiatric disorders, higher rates of alcohol and drug use, higher crime rates, unemployment and other problems that place a burden on individuals and society. Drug use during pregnancy affects both the mother and the foetus and is closely associated with perinatal problems, miscarriages, premature births, low birth weight, small head circumference and congenital malformations. Maternal drug use during pregnancy causes neonatal abstinence syndrome; it also affects foetal brain development, which can lead to long-term neuropsychiatric problems. The prevalence of alcohol and drug use among pregnant women in Slovenia has not been studied before. The adult gastrointestinal tract is densely populated by microorganisms. The microbiota, which represents a taxonomic inventory of the present microbial genera and species-primarily bacteria-and, in a broader sense, the microbiome, which encompasses all microorganisms (bacteria, archaea, fungi, protozoa, viruses, mobile genetic elements) together with their functional genes and metabolites present in the intestine, varies considerably in its composition among individuals, depending on the resolution of observation. At birth, a child's gastrointestinal tract has a lower density of microbial cells, as a network of selective pressures begins to develop only upon contact with maternal secretions, food, and the environment. These pressures include microbial fermentative products derived from breast milk or infant formula, gene expression, and microbial competition, leading to the dynamic development of the microbiome. Several factors influence the development of the infant gut microbiome after birth, including mode of delivery, type of feeding, prematurity, antibiotic use, and other environmental factors. Increasing evidence also points to the influence of prenatal factors, such as gestational diabetes and obesity, infections, stress, and maternal diet. A growing number of studies further demonstrate that an altered microbiota during pregnancy and early childhood can affect brain development and behaviour later in life via the gut-brain axis. The impact of alcohol consumption on the gut microbiota has been studied mainly in adults, in whom a reduction in microbiota α-diversity has been observed. Prenatal exposure to alcohol may influence the newborn's microbiota primarily through alcohol-induced alterations of the maternal microbiota and, consequently, nutrient absorption. Meconium analysis represents a unique opportunity to study exclusively prenatal factors affecting the microbiome, as postnatal factors do not influence the meconium microbiome. Wang and colleagues studied mother-newborn pairs by analysing maternal stool samples in the third trimester and neonatal samples within the first 48 hours after birth. They demonstrated significant differences in the microbiota composition of mothers who consumed alcohol and in the microbiota of their newborns compared with mother-newborn pairs in which the mothers did not consume alcohol. There are only a few studies in animal models that have confirmed differences in the gut microbiota of adult offspring whose mothers were fed an alcohol-containing diet during pregnancy. To date, no published studies have characterized the meconium microbiome of newborns whose mothers consumed cannabis. Methods: The prevalence of alcohol and cannabis use during pregnancy will be investigated in collaboration with the National Institute of Public Health, Institute of Forensic Medicine (IFM) of the Faculty of Medicine, University of Ljubljana, Institute Jozef Stefan and the Clinical Department of Neonatology of the Paediatric Clinic, University Clinical Centre Ljubljana, using three different methods:1. A cross-sectional study will be conducted on a nationally representative sample of meconium samples. The meconium samples will be collected from maternity hospitals in Slovenia. Biomarkers for alcohol and illicit drugs will be determined in the meconium samples. The sample size of the study will be calculated considering the population of Slovenia, the number of births per year and the estimated prevalence of alcohol and drug use during pregnancy. Meconium samples will be collected anonymously. Diapers with meconium will be collected in special waste bags by professionals caring for newborns and mothers on the first day after birth. Diapers for the meconium sampling will be randomly taken from the bags; the sample will be labelled with a serial number. Data about neonate's sex, gestational age (mature/premature), type of birth (vaginal/caesarean), antibiotic use during labour and maternal chronic diseases will be collected anonymously without any other personal or time data. One hundred meconium samples from a single maternity hospital will be paired with the mothers' questionnaires. For this sub-group of meconium samples, permission for sampling and pairing with questionnaire answers will be obtained from the mothers. Here also there will be no personal data collection, the meconium sample and mother's questionnaire will be paired through code. The samples will be analysed in the IFM toxicology laboratory. For the study, a new analytical method for the examination of meconium will be introduced in Slovenia.2. National survey on the lifestyle will be conducted in Slovenian maternity hospitals, including questions on alcohol and drug use during pregnancy. The survey will be anonymous and not related to meconium sampling; participation in the survey will be voluntary. Women will be given access to the online survey, after receiving information about the aim of the study, the method used to ensure anonymity and the collection methods.3. Microbiome analysis: all meconium samples that will test positive for alcohol and cannabis metabolites, as well as two negative meconium samples per every positive meconium sample, will be included in the analysis of meconium microbiome composition. In the final part of the study-the comparison of the microbiome-all meconium samples positive for alcohol or cannabis metabolites will be included. Microbiome analysis will be carried out in the final phase of the study within the framework of the Million Microbiomes from Humans Project consortium and the Slovenian Metabolomics Database (in preparation). The molecular data obtained from metagenomic sequencing will be analysed on the Slovenian supercomputing infrastructure (Vega, Maister) using tools developed and employed on the supercomputing network by the interdisciplinary group. The investigators will generate taxonomic matrices of bacteria, archaea, fungi, protozoa, and DNA viruses; diversity matrices (35 diversity indices); functional gene matrices (20 million groups); enzymatic reaction matrices (500,000 categories); metabolic pathway matrices (100,000 variables); and metabolite matrices (1,000 variables). The collected data and their transformation from molecular into numerical formats will serve as the basis for machine learning (standardization, normalization, evaluation of sample separation and classification performance using different algorithms and hyperparameters), identification of biomarker networks (n > 100), and nonparametric statistical analysis of the gut microbiome. Statistical analysis: Statistical data analysis will be performed using the IBM SPSS Statistics 25 software package. Descriptive statistical methods will be used to characterize the population of postpartum women participating in the survey and to summarize the collected data. The prevalence of alcohol or cannabis use among pregnant women will be calculated based on the number of meconium samples positive for alcohol or cannabis metabolites. The prevalence of alcohol and cannabis use based on self-reporting will be calculated separately. Molecular data obtained from microbiome analysis will be converted into numerical data and used for machine learning (standardization, normalization, evaluation of sample separation and classification performance using different algorithms and hyperparameters), identification of biomarker networks (n > 100), and nonparametric statistical analysis of the gut microbiome, as conducted by the interdisciplinary group. The obtained data will then be statistically compared between the group of meconium samples positive for alcohol and cannabis metabolites and the group of meconium samples in which these metabolites were not present. Expected results: To determine the prevalence of alcohol and drug use among pregnant women in Slovenia. Data on alcohol and drug metabolites obtained from meconium samples will be compared with survey results, where the prevalence of alcohol and drug use is determined by self-report. This will enable us to assess the reliability of self-reporting. The results of the study will provide an estimate of the prevalence of fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorders (FASD) in Slovenia and support the development of strategies to increase awareness among healthcare professionals and the general public regarding the prevalence and consequences of alcohol and drug use during pregnancy. The findings will also inform the planning of preventive measures and targeted interventions for pregnant women, as well as the establishment of multidisciplinary diagnostic teams for FAS and FASD. Regarding the microbiome, differences in the composition of the meconium microbiome are expected between samples testing positive for alcohol or cannabis exposure and those testing negative, while accounting for potential confounding factors, including sex, gestational age, intrapartum antibiotic exposure, and the presence of chronic maternal diseases.

Keywords
prevalence, alcohol, cannabis, microbiome, meconium, self report, pregnancy
Medical subject headings
Health Risk Behaviors, Marijuana Abuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07456579
Study groupRoleWhat they receive
Meconium samples that will not be paired with maternal questionnairesRandom meconium samples will be collected from thirteen Slovenian maternity hospitals. At the same time, maternal questionnaires will be collected. The meconium samples and the questionnaires will be collected at random and will not be paired. No personal data will be collected.
Meconium samples that will be paired with maternal questionnairesIn this group, the maternal questionnaire will be paired with the meconium sample. Mothers will first be asked to provide voluntary consent to participate in the study and will sign a written informed consent form. They will then complete the questionnaire, after which a meconium sample will be collected from their newborn. The questionnaire and meconium sample will be coded to ensure anonymity and to avoid collecting any personal data. The aim of this paired group is to evaluate the accuracy of self-reported substance use during pregnancy.
Postpartum womenPostpartum women will be invited to complete structured questionnaire addressing lifestyle factors during pregnancy, including self-reported alcohol, tobacco, and drug use.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of prenatal alcohol and cannabis exposure determined by meconium biomarkers

    Prevalence of prenatal alcohol and cannabis exposure in Slovenia, determined by the detection of alcohol and cannabis metabolites (concentration of ethyl glucuronide (EtG) and/or ethyl sulfate (EtS) exceeded 30 ng/g; delta-9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC (THC-COOH) and/or 11-hydroxy-THC (THC-OH) exceeded 10 ng/g) in newborns' meconium samples.

    Measured: From all the collected samples in one year period.

  2. Prevalence of self-reported alcohol and cannabis use during pregnancy

    Prevalence of alcohol and cannabis use during pregnancy (proportion of pregnant women reporting alcohol and cannabis use during pregnancy) in Slovenia, determined from self-reported data collected using a structured questionnaire.

    Measured: 1 year

  3. Differences in meconium microbiome composition associated with prenatal alcohol and/or cannabis exposure

    Meconium microbiome composition will be assessed by metagenomic sequencing. Taxonomic profiles (bacteria, archaea, fungi, protozoa, and DNA viruses), microbial diversity indices, functional gene profiles, enzyme reaction categories, metabolic pathways, and metabolite profiles will be generated and compared between newborns with and without prenatal alcohol and/or cannabis exposure, while accounting for potential confounding factors.

    Measured: Meconium samples collected approximately 12 months. Biomarker analyses 12 months after sample collection. Metagenomic sequencing and microbiome analyses over the subsequent 6 months.

Secondary outcomes (4)
  1. Proportion of women reporting tobacco use during pregnancy (modified CINTI questionnaire)

    Proportion of postpartum women reporting tobacco use during the three months before pregnancy and during pregnancy, assessed using the Health Behaviour during Pregnancy questionnaire (a modified CINDI questionnaire).

    Measured: One year period.

  2. Self-reported dietary habits during pregnancy

    Self-reported dietary habits during the three months before pregnancy and during pregnancy, assessed using selected items from the Health Behaviour during Pregnancy questionnaire (a modified CINDI questionnaire).

    Measured: One year period.

  3. Self-reported physical activity during pregnancy

    Self-reported physical activity during the three months before pregnancy and during pregnancy, assessed using selected items from the Health Behaviour during Pregnancy questionnaire (a modified CINDI questionnaire).

    Measured: One year period.

  4. Self-reported mental well-being during pregnancy

    Self-reported mental well-being during the three months before pregnancy and during pregnancy, assessed using selected items from the Health Behaviour during Pregnancy questionnaire (a modified CINDI questionnaire).

    Measured: One year period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2026
  2. Study start5 May 2024
  3. Primary completion1 Jun 2026
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07456579
Sponsor's protocol ID
0120-269/2023/3
Status last verified
Aug 2026
First submitted
2 Mar 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Badowski S, Smith G. Cannabis use during pregnancy and postpartum. Can Fam Physician. 2020 Feb;66(2):98-103.

    PubMed 32060189
  • Wang Y, Xie T, Wu Y, Liu Y, Zou Z, Bai J. Impacts of Maternal Diet and Alcohol Consumption during Pregnancy on Maternal and Infant Gut Microbiota. Biomolecules. 2021 Mar 1;11(3):369. doi: 10.3390/biom11030369.

    PubMed 33804345
  • Popova S, Dozet D, Akhand Laboni S, Brower K, Temple V. Why do women consume alcohol during pregnancy or while breastfeeding? Drug Alcohol Rev. 2022 May;41(4):759-777. doi: 10.1111/dar.13425. Epub 2021 Dec 28.

    PubMed 34963039
  • Upreti D, Rouzer SK, Bowring A, Labbe E, Kumar R, Miranda RC, Mahnke AH. Microbiota and nutrition as risk and resiliency factors following prenatal alcohol exposure. Front Neurosci. 2023 Jun 15;17:1182635. doi: 10.3389/fnins.2023.1182635. eCollection 2023.

    PubMed 37397440
  • Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota. Alcohol Res. 2015;37(2):223-36. doi: 10.35946/arcr.v37.2.07.

    PubMed 26695747
  • Chiandetti A, Hernandez G, Mercadal-Hally M, Alvarez A, Andreu-Fernandez V, Navarro-Tapia E, Bastons-Compta A, Garcia-Algar O. Prevalence of prenatal exposure to substances of abuse: questionnaire versus biomarkers. Reprod Health. 2017 Oct 25;14(1):137. doi: 10.1186/s12978-017-0385-3.

    PubMed 29070078
  • Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ. Role of the microbiome in human development. Gut. 2019 Jun;68(6):1108-1114. doi: 10.1136/gutjnl-2018-317503. Epub 2019 Jan 22.

    PubMed 30670574
  • Graves L, Carson G, Poole N, Patel T, Bigalky J, Green CR, Cook JL. Guideline No. 405: Screening and Counselling for Alcohol Consumption During Pregnancy. J Obstet Gynaecol Can. 2020 Sep;42(9):1158-1173.e1. doi: 10.1016/j.jogc.2020.03.002.

    PubMed 32900457
  • Chong CYL, Bloomfield FH, O'Sullivan JM. Factors Affecting Gastrointestinal Microbiome Development in Neonates. Nutrients. 2018 Feb 28;10(3):274. doi: 10.3390/nu10030274.

    PubMed 29495552
  • Joya X, Marchei E, Salat-Batlle J, Garcia-Algar O, Calvaresi V, Pacifici R, Pichini S. Fetal exposure to ethanol: relationship between ethyl glucuronide in maternal hair during pregnancy and ethyl glucuronide in neonatal meconium. Clin Chem Lab Med. 2016 Mar;54(3):427-35. doi: 10.1515/cclm-2015-0516.

    PubMed 26351940
  • Wozniak MK, Wiergowski M, Namiesnik J, Biziuk M. Biomarkers of Alcohol Consumption in Body Fluids - Possibilities and Limitations of Application in Toxicological Analysis. Curr Med Chem. 2019;26(1):177-196. doi: 10.2174/0929867324666171005111911.

    PubMed 28982313
  • Marchand G, Masoud AT, Govindan M, Ware K, King A, Ruther S, Brazil G, Ulibarri H, Parise J, Arroyo A, Coriell C, Goetz S, Karrys A, Sainz K. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022 Jan 4;5(1):e2145653. doi: 10.1001/jamanetworkopen.2021.45653.

    PubMed 35084479
  • Cristino L, Di Marzo V. Fetal cannabinoid receptors and the "dis-joint-ed" brain. EMBO J. 2014 Apr 1;33(7):665-7. doi: 10.1002/embj.201488086. Epub 2014 Mar 14.

    PubMed 24631837
  • Jarmasz JS, Basalah DA, Chudley AE, Del Bigio MR. Human Brain Abnormalities Associated With Prenatal Alcohol Exposure and Fetal Alcohol Spectrum Disorder. J Neuropathol Exp Neurol. 2017 Sep 1;76(9):813-833. doi: 10.1093/jnen/nlx064.

    PubMed 28859338
  • Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. Lancet Glob Health. 2017 Mar;5(3):e290-e299. doi: 10.1016/S2214-109X(17)30021-9. Epub 2017 Jan 13.

    PubMed 28089487

Questions about this trial

What is this clinical trial studying?

An observational study of Microbiome Analysis and Drug Abuse in Pregnancy, run by University Medical Centre Ljubljana at 1 site in Slovenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of prenatal alcohol and cannabis exposure determined by meconium biomarkers (time frame: From all the collected samples in one year period.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07456579, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in